Evaluación del estado nutricional en la enfermedad de Alzheimer y su influencia en la progresión tras el diagnóstico / Nutritional status assessment in Alzheimer disease and its influence on disease progression

Introducción: Las deficiencias nutricionales son frecuentes en la enfermedad de Alzheimer (EA), incluso en fases iniciales. El deterioro nutricional (DN) puede asociarse con una progresión más rápida de la enfermedad. El objetivo fue describir la frecuencia y los factores de riesgo asociados a DN en el momento del diagnóstico y analizar su influencia en la evolución posterior.MétodosEstudio observacional, multicéntrico, prospectivo. Se incluyeron sujetos recién diagnosticados de EA prodrómica (EAp) o demencia por EA (EAd). Se realizaron dos evaluaciones en un periodo de 18 meses. Para estimar el estado nutricional se empleó el Mini Nutritional Assessment Test (MNA, rango 0-30; DN: MNA < 24). El criterio de progresión fue un incremento en la Clinical Dementia Rating-sum of boxes ≥ 3.ResultadosSe incluyeron 50 sujetos con EAp (edad 76,1 ± 5,3 años; 68% mujeres) y 127 con EAd (edad 80 ± 5,9 años; 72,4% mujeres); 141 (79,7%) completaron las dos evaluaciones. La prevalencia de DN fue del 28,2% (EAp 24%, EAd 29,9%; p = 0,43), la mayoría (92%) en riesgo de desnutrición. El DN se asoció con el sexo femenino (OR: 4,2; IC 95%: 1,7-10,5; p < 0,001) y mayor afectación conductual (OR: 5,8; IC 95%: 2,6-12,7; p < 0,001). Se observó mayor proporción de sujetos con progresión entre los que tenían un DN respecto a estado nutricional normal (50% vs 28,7%, p < 0,05; EAd 53,6% vs 31,8%, p < 0,05; EAp 41,7% vs 22,9%; p = 0,21). Una mayor afectación cognitiva (OR: 2,1; IC 95%: 1,03-4,4; p < 0,05) y un DN (OR: 2,4; IC 95%: 1,1-5,1; p < 0,05) fueron factores de riesgo independientes de progresión.ConclusionesLa prevalencia de DN en la EA es elevada. La evaluación del estado nutricional en el momento del diagnóstico puede permitir identificar pacientes con mayor riesgo de progresión de la enfermedad. (AU)

Introduction: Nutritional deficiencies are frequent in Alzheimer disease (AD), even in early stages. Nutritional impairment (NI) may be associated with faster disease progression. The objective of this study was to describe the frequency of NI and the associated risk factors at the time of diagnosis and to analyse its influence on subsequent progression.MethodsWe performed a prospective, multicentre, observational study of patients recently diagnosed with prodromal AD (pAD) or dementia due to AD (ADd). Two clinical assessments were conducted over a period of 18 months. The Mini Nutritional Assessment test (MNA; score range, 0-30; cut-off point for NI, < 24) was used to estimate nutritional status. Progression was defined as an increase of ≥ 3 points on the Clinical Dementia Rating-sum of boxes test.ResultsThe sample included 50 patients with pAD (mean [standard deviation] age, 76.1 [5.3] years; 68% women), and 127 with ADd (80 [5.9] years; 72.4% women). A total of 141 (79.7%) completed both evaluations. The prevalence of NI was 28.2% (24% for pAD, 29.9% for ADd; P = .43), with the majority (92%) at risk of malnutrition. NI was associated with female sex (odds ratio [OR]: 4.2; 95% confidence interval [CI]: 1.7-10.5; P < .001) and greater behavioural involvement (OR: 5.8; 95% CI: 2.6-12.7; P < .001). A larger proportion of patients with progression was observed among those with NI than among those with normal nutritional status (50% vs 28.7%, P < .05; ADd: 53.6% vs 31.8%, P < .05; pAD: 41.7% vs 22.9%, P = .21). Greater cognitive impairment (OR: 2.1; 95% CI: 1.03-4.4; P < .05) and NI (OR: 2.4; 95% CI: 1.1-5.1; P < .05) were independent risk factors for disease progression.ConclusionsNI is highly prevalent in patients with AD. Assessing nutritional status at the time of diagnosis may enable identification of patients at greater risk of disease progression. (AU)

Nutritional status assessment in Alzheimer disease and its influence on disease progression.

INTRODUCTION: Nutritional deficiencies are frequent in Alzheimer disease (AD), even in early stages. Nutritional impairment (NI) may be associated with faster disease progression. The objective of this study was to describe the frequency of NI and the associated risk factors at the time of diagnosis and to analyse its influence on subsequent progression. METHODS: We performed a prospective, multicentre, observational study of patients recently diagnosed with prodromal AD (pAD) or dementia due to AD (ADd). Two clinical assessments were conducted over a period of 18 months. The Mini Nutritional Assessment test (MNA; score range, 0-30; cut-off point for NI, < 24) was used to estimate nutritional status. Progression was defined as an increase of ≥ 3 points on the Clinical Dementia Rating-sum of boxes test. RESULTS: The sample included 50 patients with pAD (mean [standard deviation] age, 76.1 [5.3] years; 68% women), and 127 with ADd (80 [5.9] years; 72.4% women). A total of 141 (79.7%) completed both evaluations. The prevalence of NI was 28.2% (24% for pAD, 29.9% for ADd; P = .43), with the majority (92%) at risk of malnutrition. NI was associated with female sex (odds ratio [OR]: 4.2; 95% confidence interval [CI]: 1.7-10.5; P < .001) and greater behavioural involvement (OR: 5.8; 95% CI: 2.6-12.7; P < .001). A larger proportion of patients with progression was observed among those with NI than among those with normal nutritional status (50% vs 28.7%, P < .05; ADd: 53.6% vs 31.8%, P < .05; pAD: 41.7% vs 22.9%, P = .21). Greater cognitive impairment (OR: 2.1; 95% CI: 1.03-4.4; P < .05) and NI (OR: 2.4; 95% CI: 1.1-5.1; P < .05) were independent risk factors for disease progression. CONCLUSIONS: NI is highly prevalent in patients with AD. Assessing nutritional status at the time of diagnosis may enable identification of patients at greater risk of disease progression.

Variaciones de la configuración ductal pancreática: factor predisponente de pancreatitis recurrente / Variations of pancreatic ductal configuration: predisposing factor of recurrent pancreatitis

El páncreas es un órgano de origen endodérmico, que se desarrolla de dos esbozos intestinales separados, uno dorsal y otro ventral,a partir de la cuarta o quinta semana de gestación. El páncreas se origina en el intestino anterior en la parte correspondiente a lafutura segunda porción duodenal. Allí se originan dos brotes: uno posterior o dorsal que aparece a principios de la cuarta semanay crece rápidamente en el mesenterio dorsal y el otro brote es anterior o ventral. Este último da origen a dos brotes, uno origina unaparte del páncreas y otro a la vía biliar e hígado. Existen diferentes variantes anatómicas, derivadas de este desarrollo embrionario;su conocimiento es de vital importancia en pacientes con persistencia de dolor abdominal y episodios de pancreatitis recurrente.El objetivo de este artículo es una revisión de las variantes anatómicas del conducto pancreático que pueden manifestarse como pancreatitis idiopática recurrente. (AU)

The pancreas is an organ of endodermal origin, which develops from two separate intestinal sketches, one dorsal and one ventral,from the fourth or fifth week of gestation. The pancreas originates in the anterior intestine in the part corresponding to the futuresecond duodenal portion. There two shoots originate: one posterior or dorsal that appears at the beginning of the fourth week andgrows rapidly in the dorsal mesentery and the other outbreak is anterior or ventral. The latter gives rise to two outbreaks, oneoriginates a part of the pancreas and another to the bile duct and liver. There are different anatomical variants, derived from thisembryonic development; their knowledge is of vital importance in patients with persistent abdominal pain and episodes of recurrentpancreatitis. The objective of this article is a review of the anatomical variants of the pancreatic duct that can manifest as recurrent idiopathic pancreatitis. (AU)

Nutritional status assessment in Alzheimer disease and its influence on disease progression. / Evaluación del estado nutricional en la enfermedad de Alzheimer y su influencia en la progresión tras el diagnóstico.

INTRODUCTION: Nutritional deficiencies are frequent in Alzheimer disease (AD), even in early stages. Nutritional impairment (NI) may be associated with faster disease progression. The objective of this study was to describe the frequency of NI and the associated risk factors at the time of diagnosis and to analyse its influence on subsequent progression. METHODS: We performed a prospective, multicentre, observational study of patients recently diagnosed with prodromal AD (pAD) or dementia due to AD (ADd). Two clinical assessments were conducted over a period of 18months. The Mini Nutritional Assessment test (MNA; score range, 0-30; cut-off point for NI, <24) was used to estimate nutritional status. Progression was defined as an increase of ≥3points on the Clinical Dementia Rating-sum of boxes test. RESULTS: The sample included 50 patients with pAD (mean [standard deviation] age, 76.1 [5.3] years; 68% women), and 127 with ADd (80 [5.9] years; 72.4% women). A total of 141 (79.7%) completed both evaluations. The prevalence of NI was 28.2% (24% for pAD, 29.9% for ADd; P=.43), with the majority (92%) at risk of malnutrition. NI was associated with female sex (odds ratio [OR]: 4.2; 95% confidence interval [CI]: 1.7-10.5; P<.001) and greater behavioural involvement (OR: 5.8; 95%CI: 2.6-12.7; P<.001). A larger proportion of patients with progression was observed among those with NI than among those with normal nutritional status (50% vs 28.7%, P<.05; ADd: 53.6% vs 31.8%, P<.05; pAD: 41.7% vs 22.9%, P=.21). Greater cognitive impairment (OR: 2.1; 95%CI: 1.03-4.4; P<.05) and NI (OR: 2.4; 95%CI: 1.1-5.1; P<.05) were independent risk factors for disease progression. CONCLUSIONS: NI is highly prevalent in patients with AD. Assessing nutritional status at the time of diagnosis may enable identification of patients at greater risk of disease progression.

Estudio de la base genética de la reducción del Trabecular Bone Score relacionada con los inhibidores de la aromatasa / Study of the genetic basis of Trabecular Bone Score reduction related to aromatase inhibitors

Objetivos: Los inhibidores de la aromatasa (AI) son terapias endocrinas adyuvantes eficaces para pacientes con cáncer de mama, aunque se han asociado a un mayor riesgo de fractura osteoporótica. Previamente se ha demostrado una pérdida en el Trabecular Bone Score (TBS) que puede variar entre las pacientes tratadas con IA. El estudio pretendió identificar la base genética asociada al cambio en el TBS mediante el estudio de genes de la vía esteroidogénica. Material y métodos: La cohorte B-ABLE estudia de forma prospectiva a mujeres postmenopáusicas con cáncer de mama en tratamiento con IA. Se calculó el TBS a partir de los datos adquiridos en la densitometría mediante absorciometría radiológica dual (DXA) realizada al inicio y al final del tratamiento con IA. El cambio relativo del TBS se calculó como la variación porcentual del valor de TBS al final de tratamiento respecto al TBS basal. Para estudiar la posible asociación genética se genotiparon los polimorfismos de cambio de un nucleótido (SNPs) en los genes CYP11A1, CYP17A1, HDE3B2, HDE17B3, CYP19A1, CYP2C19, CYP2C9, ESR1, GC, CYP27B1, VDR y CYP24A1. Se estudió mediante regresión lineal múltiple la posible relación entre genes y cambios en TBS contemplando los modelos de herencia genética dominante, recesivo y aditivo. Resultados: Se incluyeron en el estudio un total de 212 mujeres no tratadas con bisfosfonatos en las que pudo calcularse el TBS. La mitad de las pacientes habían recibido tratamiento previo con tamoxifeno. El porcentaje de cambio intra-individual del TBS fue del -0,04% [IC del 95%: -0,05 a -0,03; p<0,001] al final de tratamiento con IA. El SNP rs6013897 en el gen CYP24A1 mostró una asociación significativa con la reducción del TBS [p=0,03565; coeficiente Beta (IC del 95%) = -1,55 (-2,98 a -0,11)]. Conclusiones: El gen CYP24A1 podría estar implicado en la variabilidad fenotípica encontrada en el deterioro de la microarquitectura ósea durante el tratamiento con IA

Objectives: Aromatase inhibitors (AI) are effective adjuvant endocrine therapies for breast cancer patients, although they have been associated with an increased risk of osteoporotic fracture. Trabecular Bone Score (TBS) loss has been previously demonstrated, although it may vary among AI-treated patients. This study aims to identify the genetic basis associated with TBS change by studying steroidogenic pathway genes. Material and methods: The B-ABLE cohort studies prospectively postmenopausal women with breast cancer under treatment with AI. TBS is calculated from the raw data acquired in dual-energy x-ray absorptiometry (DXA) scan at the outset of the study and at the end of AI-treatment. The relative TBS change was calculated as the percentage variation of the TBS value at the end of treatment from baseline. To study the possible genetic association, nucleotide polymorphisms (SNPs) were genotyped in genes CYP11A1, CYP17A1, HDE3B2, HDE17B3, CYP19A1, CYP2C19, CYP2C9, ESR1, GC, CYP27B1, VDR and CYP24A1. The possible relationship between genes and TBS changes was studied by multiple linear regression, considering models of dominant, recessive and additive genetic inheritance. Results: The study included 212 women that had not been treated with bisphosphonates and had available TBS data. Half of the patients had been treated previously with tamoxifen. The percentage of intra-individual TBS change was -0.04% [95% CI: -0.05 to -0.03; p<0.001] at the end of AI treatment. The SNP rs6013897 in the gene CYP24A1 showed a significant association with TBS reduction [p=0.03565; coefficient Beta (95% CI) = -1.55 (-2.98 to -0.11)]. Conclusions: The CYP24A1 gene could be involved in the phenotypic variability found in bone microarchitecture deterioration during AI treatment

Experience with botulinum toxin in chronic migraine. / Experiencia con toxina botulínica en la migraña crónica.

OBJECTIVE: The purposes of this study were to describe our 16-month experience with onabotulinumtoxinA (OnabotA) for the treatment of chronic migraine (CM) in the Spanish province of Segovia, evaluate its benefits, and determine clinical markers of good response to treatment. PATIENTS AND METHODS: Prospective study of patients with CM who received OnabotA for 16 months. The effectiveness of OnabotA was evaluated based on the reduction in the number of headache days, pain intensity, and side effects. We used two-way analysis of variance (ANOVA) to assess the effects of treatment according to the time factor. We studied the correlation between treatment effects and other variables using a linear regression model to establish the clinical markers of good response to treatment. RESULTS: We included 69 patients who met the diagnostic criteria for CM. Patients underwent an average of 2 infiltrations. Mean age was 43 years; 88.4% were women. The number of headache days and pain intensity decreased significantly (P < .005); improvements remained over time. We found a negative correlation between the reduction in pain intensity and the number of treatments before OnabotA. CONCLUSION: The beneficial effects of OnabotA for CM continue over time. OnabotA is a safe and well-tolerated treatment whose use for refractory CM should not be delayed since early treatment provides greater benefits.

Análisis genético de enzimas de la vía esteroidal asociadas a efectos adversos musculoesqueléticos de los inhibidores de la aromatasa / Genetic analysis of steroid pathway enzymes associated with adverse musculoskeletal effects of aromatase inhibitors

Objetivos: Identificar putativas variantes funcionales en los genes CYP11A1 y CYP17A1 asociadas a efectos musculoesqueléticos (pérdida acelerada de la masa ósea y artralgias) derivados del tratamiento con inhibidores de la aromatasa (IA). Material y métodos: La cohorte B-ABLE es un estudio prospectivo de mujeres postmenopáusicas con cáncer de mama en tratamiento con IA. La densidad mineral ósea en columna lumbar y cuello femoral se midió mediante densitometría, y el dolor articular mediante escala analógica visual. A partir de polimorfismos de cambio de un nucleótido (SNPs) en los genes CYP11A1 (rs4077581, rs11632698 y rs900798) y CYP17A1 (rs4919686, rs4919683, rs4919687, rs3781287, rs10786712, rs6163, rs743572), asociados previamente con eventos musculoesqueléticos, se construyeron los haplotipos para cada paciente de la cohorte, y se seleccionaron aquellos que mostraron mayor diferencia fenotípica (p<0,05). Dentro de cada haplotipo, se eligieron aquellas pacientes con fenotipos extremos para la secuenciación de los respectivos genes y la identificación de variantes genéticas funcionales. Finalmente, se realizó un análisis de regresión lineal múltiple contemplando los modelos de herencia genética dominante, recesivo y aditivo. Resultados: No se encontró ninguna mutación en las regiones codificantes. En la región del promotor basal del gen CYP11A1 se encontró una variante genética (D15S520) asociada a la pérdida de masa ósea del cuello de fémur a los 24 meses de tratamiento con IA. Conclusiones: Variantes en regiones reguladoras del gen CYP11A1 podrían modular la expresión de este gen, explicando así parte de la variabilidad fenotípica encontrada en la pérdida de hueso de las pacientes en tratamiento con IA (AU)

Objetives: Identify putative functional variants in the CYP11A1 and CYP17A1 genes associated with musculoskeletal effects (accelerated bone mass loss and arthralgia) derived from treatment with aromatase inhibitors (AI). Material and methods: The B-ABLE cohort is a prospective study of postmenopausal women with breast cancer undergoing AI treatment. Bone mineral density in the lumbar spine and femoral neck was measured by densitometry and joint pain using visual analogue scale. From single-nucleotide polymorphisms (SNPs) in genes CYP11A1 (rs4077581, rs11632698 and rs900798) and CYP17A1 (rs4919686, rs4919683, rs4919687, rs3781287, rs10786712, rs6163, rs743572), previously associated with musculoskeletal events, haplotypes were constructed for each pacient from the cohort, and those haplotypes that showed greatest phenotypic differences were chosen (p<0.05). Within each haplotype, patients with extreme phenotypes were chosen for the sequencing of respective genes and identifying functional genetic variants. Finally, a multiple linear regression analysis was carried out considering the models of dominant, recessive and additive genetic inheritance. Results: No mutation was found in coding regions. A genetic variant (D15S520), in the basal promoter region of gene CYP11A1, was found associated with femoral neck bone loss at 24 month of AI treatment. Conclusions: Variants in regulatory regions of the CYP11A1 gene could modulate the expression of this gene, thus explaining part of the phenotypic variability found in bone loss of patients undergoing AI treatment (AU)

Hidatidosis portal con cavernomatosis secundaria / Portal hydatid with secondary cavernomatosis

No disponible

Primeras experiencias de monitorización de vancomicina en un Hospital General de Especialidades / First experiences of monitoring of vancomycin in a General Hospital of Specialties

Introducción: vancomicina es un antibiótico eficaz para el tratamiento de infecciones por gérmenes grampositivos, sin embargo la toxicidad renal asociada a su uso, ha relegado su utilización a líneas secundarias de uso. Este hecho ha consolidado el tratamiento empírico con antibióticos más caros. Objetivo: analizar los datos de monitorización de vancomicina y valorar la eficiencia frente al uso de otros antibióticos. Método: estudio observacional donde se analiza la monitorización farmacocinética de vancomicina y la eficiencia de una Unidad de Farmacocinética Clínica, con una población de 137 pacientes ingresados en un hospital general de especialidades. Resultados: la utilización de vancomicina en primera intención, supuso un ahorro de 16.472,82 € respecto al uso de daptomicina y de 83.039,83 € respecto al de linezolid. No obstante, el 18% de nuestra muestra no pudo ser tratado con vancomicina, lo que hace necesario disponer de otros fármacos

Introduction: vancomycin is an effective antibiotic for the treatment of infections due to Gram-positive germs, however renal toxicity associated with its use, has relegated its use to use secondary lines. This fact has consolidated the empirical treatment with more expensive antibiotics. Objective: to analyze the data of monitoring of vancomycin and rating the efficiency facing the use of other antibiotics. Materials and methods: observational study where discusses monitoring pharmacokinetics of Vancomycin and a unit of pharmacokinetics clinical efficiency, with a population of 137 patients admitted to a general hospital specialties. Results: the use of Vancomycin in first intention meant a savings of € 16.472,82 regarding the use of € 83.039,83 the linezolid and daptomycin. However, 18% of our sample not could be treated with Vancomycin, making it necessary to have other drugs

Análisis y evaluación de resultados tras la implantación de un programa de prescripción electrónica asistida en un hospital de tercer nivel / Analysis and evaluation of results following the implementation of a programme of e-prescribing in a tertiary hospital

Introducción: la Prescripción Electrónica Asistida (PEA), constituye en la actualidad una herramienta útil en el proceso de hospitalización. La supresión de la prescripción y/o transcripción manuscrita, ha conseguido minimizar los errores relacionados con la medicación, mitigando la constante preocupación que supone la seguridad del paciente. Objetivo: analizar los datos de intervención farmacéutica registrados tras la implantación de un software de prescripción electrónica y la seguridad que confiere al usuario. Material y método: estudio retrospectivo de cinco meses de duración, en el que se revisaron las historias clínicas electrónicas de prescripción, describiendo los errores de medicación detectados y el número de intervenciones farmacéuticas realizadas. Resultados: sobre un total de 27.533 validaciones, fueron realizadas 4.917 intervenciones farmacéuticas (IF), lo que supone 32,78 errores de medicación/día y 0,95 errores/paciente

Introduction: the Electronically Assisted Prescription (EAP) is now a useful tool in the process of hospitalization. The removal of the prescription or transcript handwritten, has managed to minimize errors related to medication, mitigating the constant concern involving the safety of the patient. Objective: to analyze data pharmaceutical intervention reported following implementation of a software for e-prescribing and the security that gives the user. Materials and methods: retrospective study of five months duration, which reviewed the electronic medical records of prescription, describing medication errors that are detected and the number of pharmaceutical interventions carried out. Results: out of a total of 27.533 validations, were performed 4.917 pharmaceutical interventions (IF), which represents 32.78 medication errors per day and 0.95 errors per patient

Evolución de la DMO durante el tratamiento con inhibidores de aromatasa y su relación con el gen CYP11A1: estudio prospectivo de la cohorte B-ABLE / BMD evolution during treatment with aromatase inhibitors and its relation to the CYP11A1 gene: prospective study in the B-ABLE cohort

Objetivos: El objetivo del estudio fue analizar los cambios en la densidad mineral ósea (DMO) a lo largo del tratamiento con inhibidores de aromatasa (IA) en la práctica clínica y evaluar la asociación entre el gen CYP11A1 y la variación de DMO al final del tratamiento. Material y métodos: La cohorte B-ABLE es un estudio prospectivo de mujeres postmenopáusicas con cáncer de mama, en tratamiento con IA. Se analizó la variación de DMO durante todo el tratamiento con IA, así como las diferencias entre las pacientes tratadas y no-tratadas previamente con tamoxifeno (TMX). Tres polimorfismos (rs4077581, rs11632698 y rs900798) del gen CYP11A1, fueron genotipados para su asociación con la variación de DMO. Resultados: Las pacientes tratadas con TMX mostraron pérdidas más aceleradas de DMO que las no tratadas previamente con TMX (60% menos en columna y 46% en fémur a los 2 años y 70% menos en columna y 63% en fémur a los 3 años). No obstante, al final del tratamiento no se detectaron diferencias significativas en la pérdida de DMO entre ambos grupos de pacientes. Los 3 polimorfismos del gen CYP11A1 resultaron significativamente asociados a la variación de DMO en fémur al final del tratamiento. Conclusiones: La DMO disminuyó de forma más acelerada en las pacientes con tratamiento previo con TMX que en las que solo recibieron AI, a pesar de que no se detectaron diferencias significativas al final de tratamiento. Polimorfismos en el gen CYP11A1 están relacionados con la variación de la DMO en respuesta al tratamiento con IA (AU)

Objectives: The aim of this study was to analyze bone mineral density (BMD) changes throughout aromatase inhibitor (AI) treatment in clinical cases and also consider its association with the CYP11A1 gene and the BMD variation after treatment. Material and methods: The B-ABLE cohort is a prospective study of postmenopausal women with breast cancer, in AI treatment. BMD variation was analyzed during AI treatment, as well as the differences those patients who were treated and not treated previously with tamoxifen (TMX). Three polymorphisms (rs4077581, rs11632698 and rs900798) of the CYP11A1 gene were genotyped for their association with BMD variation. Results: TMX-treated patients presented more rapid BMD loss than those who did not undergo prior TMX treatment (60% less in spine and 46% in femur at 2 years and 70% less in the spine and 63% in the femur at 3 years). However, no significant BMD loss was detected after treatment in either group. The 3 CYP11A1 gene polymorphisms were significantly associated with BMD variation in the femur at the end of the treatment. Conclusions: BMD was reduced more rapidly in patients with prior TMX treatment than in those who only received AI, although no significant differences were detected after treatment. The 3 CYP11A1 gene polymorphisms were associated with BMD variation in response to AI treatment (AU)

CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.

Aromatase inhibitors (AIs) used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer cause diverse musculoskeletal side effects that include bone loss and its associated fracture. About half of the 391 patients treated with AIs in the Barcelona-Aromatase induced bone loss in early breast cancer cohort suffered a significant bone loss at lumbar spine (LS) and/or femoral neck (FN) after 2 years on AI-treatment. In contrast, up to one-third (19.6% LS, 38.6% FN) showed no decline or even increased bone density. The present study aimed to determine the genetic basis for this variability. SNPs in candidate genes involved in vitamin D and estrogen hormone-response pathways (CYP11A1, CYP17A1, HSD3B2, HSD17B3, CYP19A1, CYP2C19, CYP2C9, ESR1, DHCR7, GC, CYP2R1, CYP27B1, VDR and CYP24A1) were genotyped for association analysis with AI-related bone loss (AIBL). After multiple testing correction, 3 tag-SNPs (rs4077581, s11632698 and rs900798) located in the CYP11A1 gene were significantly associated (P<0.005) with FN AIBL at 2 years of treatment. Next, CYP11A1 expression in human fresh bone tissue and primary osteoblasts was demonstrated by RT-PCR. Both common isoforms of human cholesterol side-chain cleavage enzyme (encoded by CYP11A1 gene) were detected in osteoblasts by western blot. In conclusion, the genetic association of CYP11A1 gene with AIBL and its expression in bone tissue reveals a potential local function of this enzyme in bone metabolism regulation, offering a new vision of the steroidogenic ability of this tissue and new understanding of AI-induced bone loss.

Evolution of socio-economic inequalities in mortality in small geographical areas of the two largest cities in Spain (Barcelona and Madrid), 1996-2007.

OBJECTIVES: To describe the evolution of socio-economic inequalities in mortality in small areas of two Spanish cities (Barcelona and Madrid) from 1996 to 2001 and from 2002 to 2007. STUDY DESIGN: A small-area ecological study of trends was performed, in which the units of analysis were census tracts. METHODS: The association between mortality and socio-economic deprivation was assessed through Poisson regression analysis. Models were stratified by sex, age group and period of study. The trend in inequalities in mortality was assessed by introducing an interaction term between deprivation and the period of study. RESULTS: Mortality in the most-deprived areas was significantly higher than mortality in the less-deprived areas in both periods and most age groups. However, inequalities seemed to diminish in young people and elderly women, especially in Barcelona. CONCLUSIONS: There is a need to monitor inequalities in mortality in the near future because the current financial crisis could change this situation.

Encefalopatía posterior reversible en un caso de eclampsia tardía / Posterior reversible encephalopathy in a case of late-onset eclampsia

Introducción. El síndrome de encefalopatía posterior reversible (SEPR) es un síndrome clínico-radiológico de presentación aguda o subaguda que se caracteriza por la presencia de cefalea, vómitos, crisis epilépticas, trastornos visuales y alteración del nivel de conciencia asociado a lesiones localizadas fundamentalmente en la sustancia blanca de regiones posteriores cerebrales. Caso clínico. Mujer de 32 años que desarrolló un SEPR en el período posparto secundario a eclampsia tardía. La paciente presentó 10 días después del parto un cuadro clínico consistente en cefalea, crisis epilépticas, ceguera y deterioro del nivel de conciencia. El estudio de imagen con resonancia magnética confirmó la afectación de la sustancia blanca de predominio posterior. Conclusiones. Aunque la eclampsia es una entidad típica del embarazo y puerperio inmediato, es necesario recordar que también puede producirse de forma tardía tras el parto y que puede ser la causa de otros síndromes, como el SEPR. Aunque en estos casos el pronóstico suele ser favorable, el tratamiento debe ser precoz, efectuando un rápido control de la tensión arterial y las convulsiones con el fin de evitar un daño cerebral permanente. Es necesario considerar siempre este síndrome en mujeres con crisis epilépticas u otros síntomas neurológicos durante el posparto (AU)

Introduction. Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiological syndrome with acute or subacute presenting symptoms characterised by the presence of headache, vomiting, epileptic seizures, visual disorders and altered level of consciousness associated to lesions mainly located in the white matter of the posterior regions of the brain. Case report. A 32-year-old female who developed PRES in the postpartum period secondary to late-onset eclampsia. Ten days after giving birth, the patient presented a clinical picture consisting in headache, epileptic seizures, blindness and deterioration of the level of consciousness. The magnetic resonance imaging scan confirmed the predominant involvement of posterior white matter. Conclusions. Although eclampsia is a typical condition in pregnancy and the immediate postpartum period, it must be remembered that there is also a late-onset form that may occur after the birth and might be the cause of other syndromes such as PRES. Although the prognosis in these cases is usually favourable, treatment must be established as early as possible, with rapid control of the blood pressure and seizures in order to avoid permanent brain damage. This syndrome must always be taken into account in women with epileptic seizures or other neurological symptoms during the postpartum period (AU)

[Posterior reversible encephalopathy in a case of late-onset eclampsia]. / Encefalopatia posterior reversible en un caso de eclampsia tardia.

INTRODUCTION: Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiological syndrome with acute or sub-acute presenting symptoms characterised by the presence of headache, vomiting, epileptic seizures, visual disorders and altered level of consciousness associated to lesions mainly located in the white matter of the posterior regions of the brain. CASE REPORT: A 32-year-old female who developed PRES in the postpartum period secondary to late-onset eclampsia. Ten days after giving birth, the patient presented a clinical picture consisting in headache, epileptic seizures, blindness and deterioration of the level of consciousness. The magnetic resonance imaging scan confirmed the predominant involvement of posterior white matter. CONCLUSIONS: Although eclampsia is a typical condition in pregnancy and the immediate postpartum period, it must be remembered that there is also a late-onset form that may occur after the birth and might be the cause of other syndromes such as PRES. Although the prognosis in these cases is usually favourable, treatment must be established as early as possible, with rapid control of the blood pressure and seizures in order to avoid permanent brain damage. This syndrome must always be taken into account in women with epileptic seizures or other neurological symptoms during the postpartum period.

TITLE: Encefalopatia posterior reversible en un caso de eclampsia tardia.Introduccion. El sindrome de encefalopatia posterior reversible (SEPR) es un sindrome clinico-radiologico de presentacion aguda o subaguda que se caracteriza por la presencia de cefalea, vomitos, crisis epilepticas, trastornos visuales y alteracion del nivel de conciencia asociado a lesiones localizadas fundamentalmente en la sustancia blanca de regiones posteriores cerebrales. Caso clinico. Mujer de 32 años que desarrollo un SEPR en el periodo posparto secundario a eclampsia tardia. La paciente presento 10 dias despues del parto un cuadro clinico consistente en cefalea, crisis epilepticas, ceguera y deterioro del nivel de conciencia. El estudio de imagen con resonancia magnetica confirmo la afectacion de la sustancia blanca de predominio posterior. Conclusiones. Aunque la eclampsia es una entidad tipica del embarazo y puerperio inmediato, es necesario recordar que tambien puede producirse de forma tardia tras el parto y que puede ser la causa de otros sindromes, como el SEPR. Aunque en estos casos el pronostico suele ser favorable, el tratamiento debe ser precoz, efectuando un rapido control de la tension arterial y las convulsiones con el fin de evitar un daño cerebral permanente. Es necesario considerar siempre este sindrome en mujeres con crisis epilepticas u otros sintomas neurologicos durante el posparto.

Paracetamol y fallo hepático agudo, ¿la gota que colma el vaso? / Acetaminophen and acute liver failure, was it the last thing needed?

El fallo hepático agudo (FHA) es una patología poco frecuente, pero fatal en pediatría. Su segunda causa más habitual es la tóxica, y el paracetamol es el agente más frecuente en esta edad, incluso en una dosis adecuada. Presentamos 2 casos de FHA sin etiología clara, en los que el paracetamol pudo ser determinante. El primer caso corresponde una lactante con bronquiolitis complicada con sobreinfección bacteriana, que presenta un fallo hepático agudo atribuido a una posible idiosincrasia del paracetamol, favorecida por una hipoperfusión hepática, desestimando la inestabilidad hemodinámica como única causa, dado su carácter leve y tardío. El segundo caso corresponde a otra lactante que desarrolló un FHA en el contexto de una deshidratación hipernatrémica por una gastroenteritis aguda; su estudio metabólico era compatible con un déficit de 3-OH metilglutaril-CoA liasa (no confirmado en el estudio molecular), considerándose una posible inhibición de la betaoxidación agravada por paracetamol (idiosincrasia) y favorecida por una hipoperfusión hepática ante una deshidratación severa. En ambos casos se empleó N-acetilcisteína (NAC) como parte del tratamiento del FHA y la evolución fue favorable. La acumulación del metabolito tóxico del paracetamol en un hígado previamente dañado, puede empeorar su función. Se deben solicitar sus niveles ante un FHA en los pacientes que han recibido este fármaco, considerando su toxicidad en función del tiempo transcurrido tras la administración. El tratamiento con NAC puede ser beneficioso en todo paciente con FHA (AU)

Acute liver failure (ALF) in children is a rare but often fatal condition. Drugs are the second most common identified cause in most of the series in children. Acetaminophen is the most frequent agent in these patients, even when it is administered in correct dosage. We present two acute liver failure cases without evident cause, in which acetaminophene could be a determinant agent. An infant with bronchiolitis complicated with bacterial sobreinfection, who presents ALF. ALF is attributed to possible acetominophen idiosyncrasy, enhanced by hepatic hypoperfusion; rejecting hemodynamic instability as the only cause because its mild and late nature. Another infant who presents ALF in context of hypernatremic dehidratation secondary to acute gastroenteritis. Metabolic study is compatible with a deficit of 3-OH methyl-glutaryl-CoA lyase (not confirmed by molecular study). It is considered possible b-oxidation inhibition exacerbated by acetaminophen (idiosyncrasy) and enhanced by liver hypoperfusion due to severe dehydration. In both cases, we use N-acetylcysteine (NAC) as part of ALF treatment; the course is favorable, normalizing liver function. The accumulation of acetaminophen toxic metabolite in a previously damaged liver can worsen its function. We must request its level in every patient with ALF who have received this drug, given its toxicity based on the time after administration. The administration of NAC to children with ALF not caused by acetaminophen toxicity appeared to be safe and may be associated with a better outcome (AU)

Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin.

INTRODUCTION: Our purpose is to describe the demographic, clinical and therapeutic characteristics of patients with blepharospasm (BS) and hemifacial spasm (HFS) in treatment with botulinum toxin type A (BtA). PATIENTS AND METHODS: Retrospective analysis of patients diagnosed with BS or HFS and treated with BtA in the Neurology Department at Complejo Asistencial de Segovia between March 1991 and December 2009. RESULTS: Different variables were collected from 34 patients with BS and 55 with HFS, of whom 44.1% and 32.7% respectively had been undergoing treatment with BtA for more than 10 years. Elapsed time from symptom onset to the first visit was 24 months in the BS group and 59.7 months in the HFS group. Diagnosis was given on the first visit for 76.5% of the BS patients and 90.7% of the HFS patients. Patients were referred by their primary care centres in 34.6% of the cases with BS and in 77.6% of the cases with HFS. The most commonly used BtA preparation was BOTOX(®) in both groups, and there were no cases of primary or secondary resistance. The median dose of BtA was raised gradually in both groups, and the increase was statistically significant during the early years of treatment. The most common side effect was ptosis (47.1% in BS, 32.5% in HFS). CONCLUSIONS: BS and HFS are the most common facial movement disorders. The demographic and clinical characteristics and therapeutic findings from this study show that treatment with BtA is both effective and safe over the long term.

[Contraceptive methods used by immigrant populations and conditions that influence the choice in a health area in Zaragoza]. / Métodos anticonceptivos utilizados por población inmigrante y condicionantes que influyen en su elección en un área sanitaria de Zaragoza.

BACKGROUND: The percentage of women immigrants in Spain has increased in these last years, resulting in the emergence of specific needs related to sexual and reproductive health. The objective of this article was to define the contraceptive methods used by immigrant women and the determining factors that influence their choice. To estimate the use of emergency post-coital contraception and prevalence of abortion. METHODS: A descriptive cross-sectional study using a survey was carried out in the first quarter of 2011 at the "Centro de Salud Delicias Sur" in Zaragoza, Spain. The target population were immigrant women of childbearing age between 15 and 45 years who attended the clinic. Non probability sampling was used. RESULTS: The mean age was 29.35 years (95% confidence interval (CI) = 27.95 to 30.75 years). The majority country of origin was Ecuador. Almost half the women were single and worked in paid employment. The educational level was considered as average. The average duration of residence in Spain was 5.68 years (95% CI = 4.99 to 6.37 years) and 42% of them (95% CI = 32.62 to 51.83) did not use any contraceptive method. The most used contraceptive method was the condom, followed by oral hormonal contraceptives. More than half of the women had been informed in Primary Care. Almost one third (32%) (95% CI = 23.42 to 41.60) of the women had a history of abortion. More than 19% of women (95% CI = 12.46 to 28.10) had used the emergency contraceptive method. CONCLUSION: Contraceptive methods were not used by 42% of women. The alert indicators on the failure of preventive measures in sexual health are still too high.

Evolución del desarrollo neurosensorial de los recién nacidos de peso extremadamente bajo (<1.000g) en nuestro medio / Evolution of neurosensory development of very low weight newborns (<1.000 g) in our setting

Objetivo. Estudiar la situación y evolución neurológica de los recién nacidos de peso extremadamente bajo (<1.000g) en nuestro medio. Material y métodos. Estudio retrospectivo sobre la evolución de 148 RNMBP nacidos entre 1993-2004 después de un período de seguimiento de aproximadamente 27,5 meses. Se realizó estudio estadístico con el programa SPSS 15.0 para Windows de un amplio número de variables correspondientes a gestación, parto, edad gestacional, peso al nacimiento, complicaciones postnatales y evolución neurológica. Las secuelas se clasificaron leves, moderadas y graves según las alteraciones funcionales y necesidades del paciente y las alteraciones ecográficas por la gravedad de las lesiones. Se analizaron también la incidencia y mortalidad de los recién nacidos de peso extremadamente bajo. Resultados. La incidencia de los RNEBP se ha ido incrementado en los últimos años, alcanzándose un máximo de 11,3% en el 2007 así como su supervivencia, siendo esta del 45% en el 2005, 62,5% en 2006 y del 82% en el 2008. Resaltaba alto porcentaje de pretérmino de bajo peso gestacional (BPEG), gestaciones múltiples, embarazos por reproducción asistida, patología obstétrica, cesáreas, complicaciones neurológicas y extraneurológicas y tratamiento recibidos. El porcentaje global de secuelas fue del 42%, clasificándose como leves el 55,9%, moderadas el 25,5%, y graves el 18,6%. En relación al tipo de secuela, predominaron las motoras puras (45%), seguidas por las mixtas 824%) y plurideficiencias (14%). Hipoacusia neurosensorial en un 4% de la población y de retinopatía en el 43,2%. El 27% cumplían criterios de parálisis cerebral, predominando la tetraparesia. El 53,7% presentó alteraciones en la ecografía transfontanelar (HPIV 31,7%, LPV 12,8%, ventriculomegalia 26,3%, hidrofelaia posthemorragica (4,1%). Tuvieron alta correlación estadística con la aparición de secuelas especialmente la edad gestacional y las alteraciones ecográficas, así como los días de ventilación mecánica y de ingreso en UCI, la membrana hiailina, displasia broncopulmonar, persistencia de ductus arterioso, enterocolitis necrotizante y diversos tratamientos. Conclusiones. Se observa un incremento en la incidencia y supervivencia de los prematuros de pesio extremadamente bajo en nuestro medio. La proporción de secuelas es alta en relación con otras series, predominando las leves o no discapacitantes y se relacionan principalmente con la edad gestacional y la patología que presentan, principalmente del sistema nervioso central (AU)

Objective. To study the neurological evolution and situation of extremely low birth weight (<1.000 g) newborn in our area. Patients and Methods. Retrospective study of the evolution of 148 ELBW born between 1993-2004 after a follow up period of approximately 27.5 months. The statistical study was done with SPSS 15.0 and Windows. Many variables were studied related to pregnancy, delivery, gestational age, birth weights, postnatal complications and neurodevelopmental evolution. The disability was classified as mild, moderate and severe according to functional alterations and patient needs; and ultra sound abnormalities depending on severity of injuries. The prevalence and mortality of ELBW newborn were also analyzed. Results. The ELBW incidence has increased during the last years, reaching a maximum of 11,3% in 2007 and as well as their survival, this being 45% in 2005, 62,5% in 2006 and 82% in 2008. It is remarkable the high percentage of low weight, multiple gestations, assisted reproduction, obstetric pathology, caesareans, neurological and extraneurological complications and treatments received. Neurodevelopmental disability was detected in 42%, being mild in 55,9%, moderate in 25,5% and severe in 18,6%. In relation to the type of disability, pure motor predominated (45%), followed by mixed disabilities (24%) and multiple disabilities (14%). Neurosensorial deafness in 4% of the population and premature retinopathy in 43.2%. Cerebral palsy in 27%, being the most frequent the tetraparesis. 52,7% had abnormalities on transfontanelle ultrasound (intraventricular hemorrhage 31.7%, 12.8% leukomalacia, ventriculomegaly 26.3%, post-hemorrhages hydrocephalus (4.1%). Te sequelae had high statistical correlation with the gestational age, the ultrasound abnormalities and the days of mechanical ventilation and ICU stay, membrane hyaline disease and bronchopulmonary dysplasia. Conclusions. We have observed an increment in the incidence and survival of the ELBW newborn in our area. The proportion of sequelae is high in relation to other series with a predominance of mild sequelae. The most predictive variables are gestacional age and pathology, especially in the central nervous system (AU)

Social inequalities in health among adolescents in a large southern European city.

BACKGROUND: Numerous health problems are initiated in childhood and adolescence. For example, obesity, which has increased significantly in recent years, often begins in early life. The objective of this study is to describe social inequalities in obesity and other health problems among adolescents, by sex. METHODS: Data were from a cross-sectional study conducted in a representative sample of 903 adolescents aged 12-16 years old, from secondary schools in Barcelona, Spain. Associations between socioeconomic indicators and health outcomes (perceived health status, and overweight and obesity) were examined through generalised estimating equation models. All analyses were stratified by sex. RESULTS: Boys were more likely to report very good perceived health status than girls (64.1% and 46.3%, respectively). Some of the less privileged socioeconomic position indicators were associated with the presence of overweight and obesity (prevalence ratio 2.41 for low family affluence scale in girls), and with a lower probability of reporting very good perceived health status among boys (prevalence ratio 0.75 for primary level of paternal education). CONCLUSIONS: This study suggests that there are social inequalities in perceived health status, overweight and obesity, measured by different socioeconomic indicators among the adolescent population of Barcelona, and that these inequalities were distributed differently among boys and girls. Gender differences in the impact of socioeconomic variables in health need to be considered in epidemiological and intervention studies.